SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001746473-23-000062
Filing Date
2023-10-03
Accepted
2023-10-03 16:53:50
Documents
15
Period of Report
2023-09-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plrx-20230928.htm   iXBRL 8-K 36616
2 EX-10.1 LEASE AGREEMENT lease-331oysterpoint.htm EX-10.1 676166
3 EX-10.2 TERMINATION terminationagreement-littl.htm EX-10.2 30829
7 image_1a.jpg GRAPHIC 116
  Complete submission text file 0001746473-23-000062.txt   993374

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT plrx-20230928.xsd EX-101.SCH 1904
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT plrx-20230928_lab.xml EX-101.LAB 23834
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT plrx-20230928_pre.xml EX-101.PRE 12510
9 EXTRACTED XBRL INSTANCE DOCUMENT plrx-20230928_htm.xml XML 2735
Mailing Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 650-481-6770
PLIANT THERAPEUTICS, INC. (Filer) CIK: 0001746473 (see all company filings)

IRS No.: 474272481 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39303 | Film No.: 231304876
SIC: 2834 Pharmaceutical Preparations